224 related articles for article (PubMed ID: 26181202)
1. Targeting Mdmx to treat breast cancers with wild-type p53.
Haupt S; Buckley D; Pang JM; Panimaya J; Paul PJ; Gamell C; Takano EA; Lee YY; Hiddingh S; Rogers TM; Teunisse AF; Herold MJ; Marine JC; Fox SB; Jochemsen A; Haupt Y
Cell Death Dis; 2015 Jul; 6(7):e1821. PubMed ID: 26181202
[TBL] [Abstract][Full Text] [Related]
2. Induction of p53 expression and apoptosis by a recombinant dual-target MDM2/MDMX inhibitory protein in wild-type p53 breast cancer cells.
Geng QQ; Dong DF; Chen NZ; Wu YY; Li EX; Wang J; Wang SM
Int J Oncol; 2013 Dec; 43(6):1935-42. PubMed ID: 24126697
[TBL] [Abstract][Full Text] [Related]
3. Context-dependent roles of MDMX (MDM4) and MDM2 in breast cancer proliferation and circulating tumor cells.
Gao C; Xiao G; Piersigilli A; Gou J; Ogunwobi O; Bargonetti J
Breast Cancer Res; 2019 Jan; 21(1):5. PubMed ID: 30642351
[TBL] [Abstract][Full Text] [Related]
4. Estrogen receptor alpha (ERα/ESR1) mediates the p53-independent overexpression of MDM4/MDMX and MDM2 in human breast cancer.
Swetzig WM; Wang J; Das GM
Oncotarget; 2016 Mar; 7(13):16049-69. PubMed ID: 26909605
[TBL] [Abstract][Full Text] [Related]
5. FL118 induces p53-dependent senescence in colorectal cancer cells by promoting degradation of MdmX.
Ling X; Xu C; Fan C; Zhong K; Li F; Wang X
Cancer Res; 2014 Dec; 74(24):7487-97. PubMed ID: 25512388
[TBL] [Abstract][Full Text] [Related]
6. A small-molecule p53 activator induces apoptosis through inhibiting MDMX expression in breast cancer cells.
Wang H; Yan C
Neoplasia; 2011 Jul; 13(7):611-9. PubMed ID: 21750655
[TBL] [Abstract][Full Text] [Related]
7. Amplification of Mdmx and overexpression of MDM2 contribute to mammary carcinogenesis by substituting for p53 mutations.
Yu Q; Li Y; Mu K; Li Z; Meng Q; Wu X; Wang Y; Li L
Diagn Pathol; 2014 Mar; 9():71. PubMed ID: 24667108
[TBL] [Abstract][Full Text] [Related]
8. A small-molecule inhibitor of MDMX activates p53 and induces apoptosis.
Wang H; Ma X; Ren S; Buolamwini JK; Yan C
Mol Cancer Ther; 2011 Jan; 10(1):69-79. PubMed ID: 21075910
[TBL] [Abstract][Full Text] [Related]
9. p53 in breast cancer subtypes and new insights into response to chemotherapy.
Bertheau P; Lehmann-Che J; Varna M; Dumay A; Poirot B; Porcher R; Turpin E; Plassa LF; de Roquancourt A; Bourstyn E; de Cremoux P; Janin A; Giacchetti S; Espié M; de Thé H
Breast; 2013 Aug; 22 Suppl 2():S27-9. PubMed ID: 24074787
[TBL] [Abstract][Full Text] [Related]
10. MDMX regulation of p53 response to ribosomal stress.
Gilkes DM; Chen L; Chen J
EMBO J; 2006 Nov; 25(23):5614-25. PubMed ID: 17110929
[TBL] [Abstract][Full Text] [Related]
11. Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity.
Danovi D; Meulmeester E; Pasini D; Migliorini D; Capra M; Frenk R; de Graaf P; Francoz S; Gasparini P; Gobbi A; Helin K; Pelicci PG; Jochemsen AG; Marine JC
Mol Cell Biol; 2004 Jul; 24(13):5835-43. PubMed ID: 15199139
[TBL] [Abstract][Full Text] [Related]
12. Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX.
Hu B; Gilkes DM; Chen J
Cancer Res; 2007 Sep; 67(18):8810-7. PubMed ID: 17875722
[TBL] [Abstract][Full Text] [Related]
13. Benzimidazoles Downregulate Mdm2 and MdmX and Activate p53 in MdmX Overexpressing Tumor Cells.
Mrkvová Z; Uldrijan S; Pombinho A; Bartůněk P; Slaninová I
Molecules; 2019 Jun; 24(11):. PubMed ID: 31181622
[TBL] [Abstract][Full Text] [Related]
14. Novel simplified yeast-based assays of regulators of p53-MDMX interaction and p53 transcriptional activity.
Leão M; Gomes S; Soares J; Bessa C; Maciel C; Ciribilli Y; Pereira C; Inga A; Saraiva L
FEBS J; 2013 Dec; 280(24):6498-507. PubMed ID: 24119020
[TBL] [Abstract][Full Text] [Related]
15. Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms.
Wang H; Nan L; Yu D; Agrawal S; Zhang R
Clin Cancer Res; 2001 Nov; 7(11):3613-24. PubMed ID: 11705884
[TBL] [Abstract][Full Text] [Related]
16. MDM4 is a rational target for treating breast cancers with mutant p53.
Miranda PJ; Buckley D; Raghu D; Pang JB; Takano EA; Vijayakumaran R; Teunisse AF; Posner A; Procter T; Herold MJ; Gamell C; Marine JC; Fox SB; Jochemsen A; Haupt S; Haupt Y
J Pathol; 2017 Apr; 241(5):661-670. PubMed ID: 28097652
[TBL] [Abstract][Full Text] [Related]
17. Regulation of MDMX expression by mitogenic signaling.
Gilkes DM; Pan Y; Coppola D; Yeatman T; Reuther GW; Chen J
Mol Cell Biol; 2008 Mar; 28(6):1999-2010. PubMed ID: 18172009
[TBL] [Abstract][Full Text] [Related]
18. First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models.
Pairawan S; Zhao M; Yuca E; Annis A; Evans K; Sutton D; Carvajal L; Ren JG; Santiago S; Guerlavais V; Akcakanat A; Tapia C; Yang F; Bose PSC; Zheng X; Dumbrava EI; Aivado M; Meric-Bernstam F
Breast Cancer Res; 2021 Mar; 23(1):29. PubMed ID: 33663585
[TBL] [Abstract][Full Text] [Related]
19. A tryptophanol-derived oxazolopiperidone lactam is cytotoxic against tumors via inhibition of p53 interaction with murine double minute proteins.
Soares J; Raimundo L; Pereira NA; dos Santos DJ; Pérez M; Queiroz G; Leão M; Santos MM; Saraiva L
Pharmacol Res; 2015; 95-96():42-52. PubMed ID: 25814188
[TBL] [Abstract][Full Text] [Related]
20. Validation of MdmX as a therapeutic target for reactivating p53 in tumors.
Garcia D; Warr MR; Martins CP; Brown Swigart L; Passegué E; Evan GI
Genes Dev; 2011 Aug; 25(16):1746-57. PubMed ID: 21852537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
